Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas

Clinics

Volumn 67, Issue 5, 2012, Pages 483-488

  Cunha, Lucas Leite ^a   Morari, Elaine Cristina ^a   Nonogaki, Suely ^b   Soares, Fernando Augusto ^c   Vassallo, José ^a   Ward, Laura Sterian ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Differentiated thyroid carcinoma; FoxP3; Regulatory T lymphocytes

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; ARTICLE; CARCINOMA; CELL DIFFERENTIATION; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHODOLOGY; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; REGULATORY T LYMPHOCYTE; STATISTICAL MODEL; THYROID TUMOR; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; T-LYMPHOCYTES, REGULATORY; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84863911981     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(05)13     Document Type: Article

References (33)

1. Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4(11):889-99, http://dx.doi.org/10.1038/nri1488.
2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61, http://dx.doi.org/10.1126/science.1079490.
3. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004;6(8):745-51, http://dx.doi.org/10.1016/j.micinf.2004.02.020.
4. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27(1):68-73, http://dx.doi.org/10.1038/83784.
5. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, et al. Foxp3 expression in human cancer cells. J Transl Med. 2008;6:19, http://dx.doi.org/10.1186/1479-5876-6-19.
6. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-8, http://dx.doi.org/10.1007/s00262-006-0225-8.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-9, http://dx.doi.org/10.1038/nm1093.
8. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214:229-38, http://dx.doi.org/10.1111/j.1600-065X.2006.00445.x.
9. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-93, http://dx.doi.org/10.1200/JCO.2006.09.4565.
10. Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C, et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol. 2010;136(10):1585-95, http://dx.doi.org/10.1007/s00432-010-0816-9.
11. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res. 2008;14(7):2028-35, http://dx.doi.org/10.1158/1078-0432.CCR-07-4554.
12. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350-66, http://dx.doi.org/10.1002/path.2774.
13. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186-92, http://dx.doi.org/10.1200/JCO.2008.18.7229.
14. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103, http://dx.doi.org/10.1038/bjc.2011.189.
15. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab. 1995;80(12):3421-4, http://dx.doi.org/10.1210/jc.80.12.3421.
16. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, et al. Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab. 2001;86(3):1346-54, http://dx.doi.org/10.1210/jc.86.3.1346.
17. Modi J, Patel A, Terrell R, Tuttle RM, Francis GL. Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. J Clin Endocrinol Metab. 2003;88(9):4418-25, http://dx.doi.org/10.1210/jc.2003-030342.
18. Ramos AM, Sales Ade O, Barbalho de Mello LE, Cirino de Andrade M, Pinto Paiva F, Ramos CC, et al. Absence of peritumoral fibrosis or inflammatory infiltrate may be related to clinical progression of papillary thyroid microcarcinoma. Int J Surg Pathol. 2009;17(6):432-7, http://dx.doi.org/10.1177/1066896909333749.
19. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95(5):2325-33, http://dx.doi.org/10.1210/jc.2009-2564.
20. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214, http://dx.doi.org/10.1089/thy.2009.0110.
21. Kasagi K, Kousaka T, Higuchi K, Iida Y, Misaki T, Alam MS, et al. Clinical significance of measurements of antithyroid antibodies in the diagnosis of Hashimoto's thyroiditis: comparison with histological findings. Thyroid. 1996;6(5):445-50, http://dx.doi.org/10.1089/thy.1996.6.445.
22. Shaha AR. TNM classification of thyroid carcinoma. World J Surg. 2007;31(5):879-87. Epub 2007/02/20.
23. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27(11):1746-52, http://dx.doi.org/10.1200/JCO.2008.17.9036.
24. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007;67(17):8344-50, http://dx.doi.org/10.1158/0008-5472.CAN-06-3304.
25. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2011.
26. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009;16(4):336-46, http://dx.doi.org/10.1016/j.ccr.2009. 08.016.
27. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;125(1):65-72, http://dx.doi.org/10.1007/s10549-010-0831-1.
28. Lopes JE, Torgerson TR, Schubert LA, Anover SD, Ocheltree EL, Ochs HD, et al. Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J Immunol. 2006;177(5):3133-42.
29. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;129(7):1275-86, http://dx.doi.org/10.1016/j.cell.2007.04.034.
30. Ban Y, Tozaki T, Tobe T, Ban Y, Jacobson EM, Concepcion ES, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. Journal of autoimmunity. 2007;28(4):201-7, http://dx.doi.org/10.1016/j.jaut.2007.02.016.
31. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34(6):1192-202, http://dx.doi.org/10.1007/s00268-009-0364-0.
32. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28, http://dx.doi.org/10.1016/0002-9343(94)90321-2.
33. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22(6):395-404. Epub 2010/07/16.